Elanco Animal Health, Inc. Q3 FY2026 earnings call

• Innovation Leadership: The 'Big Six' innovation products generated $328 million in revenue (+40% YoY). Zenrelia exceeded expectations globally, achieving record market share in the U.S. and rapid adoption in Europe. Credelio Quattro became Elanco’s largest U.S. pet health product, surpassing Seresto on a trailing four-quarter basis.
• New Product Launches: Bofrena transitioned from phased to full-scale national launch preparation for Q1 2027, with supply chain issues resolved. AdTab continues to be the fastest-growing major brand in the European OTC ecto category.
• Strategic Priorities: Management emphasizes 'Best Medicine' over price competition, citing resilient pet owner spending (93% maintaining/increasing spend) and declining reliance on vet visit volumes due to omni-channel expansion.
• Productivity & Cash Flow: Gross margin expanded 300 bps to 56.1%. Net leverage dropped to 2.9x, accelerating debt paydown ($216M in Q3). Free cash flow reached $362 million YTD, tracking ahead of the $1B target by 2028.
• Pipeline & AI: Launched an AI-driven regulatory submission tool in R&D to accelerate speed-to-market. Pipeline remains robust with no attrition since December 2025 Investor Day.

Total Revenue: $1.265 billion, up 11% reported and 9% organic constant currency. U.S. Pet Health: 13% organic growth, driven by Zenrelia and Credelio Quattro; retail sales were slightly negative but vet clinic sales were strong. International Pet Health: 17% organic constant currency growth, led by Zenrelia and AdTab. U.S. Farm Animal: 7% growth (10% including acquisitions), led by cattle. International Farm Animal: 1% organic growth (4% including acquisitions/HV), with strength in ruminants/LATAM offsetting poultry/swine weakness.

• Full Year 2026: Raised guidance significantly. Organic constant currency revenue growth expected at ~8% (previously 6-7%). Reported revenue target raised to $5.155B–$5.18B. Adjusted EBITDA midpoint increased by ~$35M (17% growth). Adjusted EPS raised by 6 cents to $1.17–$1.20.
• Q1 2027: Reported revenue expected between $1.19B and $1.215B (organic CC growth 4-6%). Operating expenses up ~11% CC. Adjusted EBITDA expected at $185M–$200M. Adjusted EPS expected at $0.16–$0.19.
• Long-Term Algorithm: Reaffirmed commitment to mid-single-digit organic revenue growth, high single-digit adjusted EBITDA growth, and low double-digit adjusted EPS growth through 2028.
• Margin Outlook: Expects structural margin improvements from 'Elanco Ascend' productivity initiatives ($200M-$250M savings by 2030), partially offset by dilutive per-front volume growth from new launches like Bofrena.

• Competitive Dynamics: Increased competition in DERM (Zenrelia/Bofrena) and broad-spectrum markets (Credelio Quattro vs. incumbents). Some time-bound promotional activities observed in general practices.
• Channel Shifts: Retail inventory drawdowns impacting Seresto sales; Costco non-renewal of agreement impacting Q1 2027 retail distribution.
• Farm Animal Cycles: Regional volatility in dairy (oversupply) and swine (China challenges) may cause quarter-on-quarter fluctuations despite long-term protein consumption tailwinds.
• Macro Environment: Persistent inflationary pressures on input costs, though largely mitigated by pricing power and procurement efficiencies.

Q: Analyst asked about gross margin traction and timing for the 60% runway goal. / A: CFO cited 300bps expansion driven by price, favorable mix, and manufacturing improvements via Elanco Ascend. Inventory cost impacts are fully behind them. Continued margin enhancement is expected over several years as volume improves and procurement partnerships yield benefits.

Q: Analyst asked about Costco non-renewal and why it happens. / A: CEO stated retail demand remains strong. Costco will pull back next year, impacting primarily Q1 2027. This will be offset by other distribution partners picked up (e.g., Dollar General). Net-net impact is positive, and Elanco maintains a long-term view on relationships.

Q: Analyst questioned if Elanco is peaking in share shift and concerns over macro/vet visit declines. / A: CEO argued vet visits are not the lead indicator; willingness to spend and convenience are. Pet owner surveys show >90% protecting/increasing spend. In broad-spectrum/DERM, Elanco is gaining share against incumbents despite market slowing in US, with international markets growing double digits.

Q: Analyst asked for breakdown of 2027 top-line growth between pet and farm. / A: CFO expects Pet to outperform Farm due to tough comps in Farm (accelerated shipments in Q1 2026 lapping). Farm will return to mid-single-digit growth. Pet health will benefit from Bofrena launch and sustained demand for existing innovations.

Q: Analyst asked about stocking/destocking trends and distributor dynamics for 2027. / A: CEO and CFO confirmed no unusual stocking or destocking in Q3, Q4, or projected into 2027. Inventories remain steady. Competition is responsible; Elanco wins via medical differentiation and share of voice rather than price cuts.